Ultrasound-guided intra-articular triamcinolone acetonide injection for treat…

To investigate the efficiency and clinical safety of intra-articular triamcinolone acetonide (TA) injection under the guide of ultrasonography combined with standard treatment for treating refractory small joints arthritis in rheumatoid arthritis (RA) patients. TA was injected upon confirmation of the needle inserting into the articular cavity. The dose was 40mg for the wrist, 20mg for the m…

COMPARED EFFICACY OF INTRA-ARTICULAR INJECTION OF METHYLPREDNISOLONE AND TRIA…

To compare the effect of two different corticosteroid types in bilateral and symmetrical knee osteoarthritis (OA). Methods: One hundred and twenty-six patients received injections of methylprednisolone acetate (MP) in one knee and triamcinolone hexacetonide (TH) in the contralateral knee. Patients were evaluated before injection and 2, 4, 8, 12, and 24 weeks after. Results: Mean patient age …

The comparison of dexamethasone and triamcinolone periarticular administratio…

Intraoperative periarticular injection of corticosteroid efectively reduces perioperative pain in total knee arthroplasty (TKA). However, which corticosteroid is most efective for intraoperative periarticular injection remains controversial. We compared the efects of corticosteroids between dexamethasone and triamcinolone acetonide periarticular administration for reducing pain and postoperativ…

Triamcinolone Acetonide Extended‑Release: A Review in Osteoarthritis Pain o…

Triamcinolone acetonide extended-release (ER) 32 mg (Zilretta®) is approved in the USA for the management of osteoarthritis (OA) pain of the knee and is administered as a single, 5 mL intra-articular (IA) injection. Although the therapeutic effects from IA corticosteroids are typically short-lived, triamcinolone acetonide ER is formulated in poly (lactic-co-glycolic acid) (PLGA) microsphere…

Intramuscular High-Dose Triamcinolone Acetonide in the Treatment of Severe Ch…

We describe our experience with administering intramuscular triamcinolone acetonide to 22 steroiddependent patients with asthma. These patients represent the minority of those with asthma whose disease is characterized by frequent emergency department visits, hospital admissions, and long-term dependency on oral corticosteroid therapy. The participants were randomly assigned to 2 treatment grou…

Intramuscular triamcinolone acetonide in chronic severe asthma

Seventeen subjects with chronic severe asthma completed a 48 week prospective, double blind study with crossover of treatment at 24 weeks, in which triamcinolone acetonide 80 mg intramuscularly every four weeks was compared with oral prednisolone 10 mg daily. Spirometry, twice daily measurements of peak expiratory flow rate, and self assessment of asthma symptom scores showed significant impro…

Triamcinolone in Asthma and Secondary Bronchospastic Pulmonary Emphysema

Triamcinolone possesses, in common with other clinically useful corticosteroids, the striking ability to curtail the allergic reaction irrespective of wide differences in precipitating factors and in responsiveness to other forms of therapy. Palliative effects in bronchial asthma have been induced promptly following the administration of comparatively small doses” and it is a recent observati…

High dose intramuscular triamcinolone in severe, chronic, life-threatening as…

Edition

-

ISBN/ISSN

-

Collation

-

Series Title

-

Call Number

-

GISSI-2: A factorial randomised trial of alteplase versus streptokinase and h…

A multicentre, randomised, open trial with a 2 x 2 factorial design was conducted to compare the benefits and risks of two thrombolytic agents, streptokinase (SK, 1·5 MU infused intravenously over 30-60 min) and alteplase (tPA, 100 mg infused intravenously over 3 h) in patients with acute myocardial infarction admitted to coronary care units within 6 h from onset of symptoms. The patients were…

ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activa…

41 299 patients entering 914 hospitals up to 24 h (median 4 h) after the onset of suspected acute myocardial infarction were randomised between streptokinase (SK: 1·5 MU infused over about 1 h), tissue plasminogen activator (tPA, duteplase: 0·60 MU/kg infused over about 4 h), or anisoylated plasminogen-streptokinase activator complex (APSAC, anistreplase: 30 U over about 3 min).